Immutep to Participate in Upcoming Investor Conferences
Provided By GlobeNewswire
Last update: Aug 7, 2024
SYDNEY, AUSTRALIA, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces its management will present at the following investor conferences:
Read more at globenewswire.com
